Lunai Bioworks (NASDAQ:LNAI) Releases Quarterly Earnings Results

Lunai Bioworks (NASDAQ:LNAI) posted its earnings results on Friday, May 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.02 million for the quarter.

Lunai Bioworks Stock Up 10.2%

Shares of NASDAQ LNAI traded up $0.27 during midday trading on Tuesday, reaching $2.88. 63,578 shares of the company were exchanged, compared to its average volume of 1,499,423. Lunai Bioworks has a one year low of $1.21 and a one year high of $31.04. The stock has a market cap of $13.02 million, a P/E ratio of -7.19 and a beta of 0.40. The stock’s 50-day moving average price is $2.57 and its 200-day moving average price is $4.86.

Analysts Set New Price Targets

LNAI has been the subject of a number of recent research reports. Wall Street Zen raised shares of Lunai Bioworks to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Lunai Bioworks in a research note on Friday, April 10th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of Lunai Bioworks

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC bought a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned approximately 0.87% of Lunai Bioworks at the end of the most recent reporting period. Institutional investors own 71.41% of the company’s stock.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.